John Goodchild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Abstract: Disclosed are stabilized ribozyme analogs having the ability to endonucleolytically cleave a sequence of 3' to 5' linked ribonucleotides. These ribozyme analogs include modifications at specific loop, catalytic core, and flanking region nucleotides which makes them more resistant to nucleases. Also disclosed are methods of preparing and utilizing the ribozyme analogs of the invention, and pharmaceutical formulations and kits containing such ribozyme analogs.
Abstract: Transposable linkers are DNA sequences recognized and employed by transposition proteins, including transposases, in the insertion of genetic information into the genetic architecture of an organism and in the movement of genetic information from one location to another in the genetic architecture of an organism. Such linkers, comprising the extreme ends of transposons, often referred to as left and right attachment sites, have been isolated from the intervening material in transposons to produce a basic building block comprising simply the extreme ends of the transposons fused together. Using restriction endonuclease recognition sites outside and between the left and right attachment sites it is possible to introduce desired genes directly or via cloning vehicles, into the genetic material of an organism.
June 10, 1987
Date of Patent:
May 16, 1989
Canadian Patents and Development Ltd., Cold Spring Harbor Laboratory
Saran A. Narang, John Goodchild, Ahmad I. Bukhari, deceased
Abstract: Inhibition of HTLV-III by adminstration of an oligonucleotide complementary to highly conserved regions of the HTLV-III genome necessary for HTLV-III replication and/or gene expression is described, as are oligodeoxynucleotide sequences which are complementary to those regions, methods of inhibiting HTLV-III replication and gene expression and methods of determining the presence or absence of HTLV-III virus in samples such as blood, saliva, urine and tears.
May 23, 1986
Date of Patent:
February 21, 1989
Worcester Foundation for Experimental Biology